Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,043 public trials 568 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

NCT00689936

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of AL Birmingham Birmingham, Alabama, United States
  • Cedar Sinai Medical Center Dept of Medicine Los Angeles, California, United States
  • University of California, San Francisco- California San Francisco, California, United States
  • Stanford University Stanford Stanford, California, United States
View all 288 locations
View Trial Details
Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

NCT00622336

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Republican Clinical Hospital #1 Izhevsk, Russia
  • Nizhny Novgorod Clinical Hospital n.a.Semashko Nizhny Novgorod, Russia
  • Novosibirsk State Regional Clinical Novosibirsk, Russia
  • Samara Regional Clinical Hospital Samara, Russia
View Trial Details
Completed

A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma

NCT00928486

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Nagoya Medical Center Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • Fukuoka University Hospital Fukuoka, Japan
  • Kyoto Prefectural University of Medicine Kyoto, Japan
View Trial Details
Completed

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Greenbrae, California, United States
  • Los Angeles, California, United States
  • Indianapolis, Indiana, United States
  • Albuquerque, New Mexico, United States
View all 80 locations
View Trial Details
Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626

Conditions
AML, Blood Protein Disorders, Cardiovascular Diseases, +28 more
Locations
  • Sutter East Bay Hospitals Berkeley, California, United States
  • Palm Springs Research Institute Hialeah, Florida, United States
  • MCG Cancer Center Augusta, Georgia, United States
  • Joliet Oncology-Hematology Associates, Ltd. Joliet, Illinois, United States
View Trial Details
Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

NCT01324947

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Royal Adelaide Hospital - SA Pathology Haematology Adelaide, Australia
  • Princess Alexandra Hospital - Haematology Brisbane, Australia
  • Royal Prince Alfred Hospital - Institute of Haematology Camperdown, Australia
  • Peter McCallum Cancer Institute - Directorate of Cancer Medicine East Melbourne, Australia
View all 91 locations
View Trial Details
Completed

Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies

NCT02164071

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Bronchial Diseases, +31 more
Locations
  • Hospital Txagorritxu Vitoria-Gasteiz, Alava, Spain
  • Hospital Sant Joan de Deu Espluges de Llobregat, Barcelona, Spain
  • Hospital Duran I Reynals L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Parc Tauli Sabadell, Barcelona, Spain
View all 22 locations
View Trial Details
Completed

Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

NCT00452569

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Clinic of Haematology, University Multiprofiled Hospital for Active Treatment "G. Stranski" Pleven, Bulgaria
  • Clinic of Haematology, University Multiprofiled Hospital for Active Treatment Plovdiv, Bulgaria
  • University of Multiprofiled Hospital for Active Treatment "Alexandrovska" - Sofia Sofia, Bulgaria
  • Military Medical Academy/Dept Haematology and Oncology Sofia, Bulgaria
View all 86 locations
View Trial Details
Completed

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

NCT02290431

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Novartis Investigative Site Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site Kashiwa, Chiba, Japan
  • Novartis Investigative Site Matsuyama, Ehime, Japan
  • Novartis Investigative Site Fukuoka, Japan
View all 20 locations
View Trial Details

Related conditions